{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-26-000013","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-08-11T20:07:48+00:00","discovered_at":"2026-08-11T20:09:01.355748+00:00","generated_at":"2026-08-11T20:09:23.406001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"SELLAS Q2 2026 net loss $9.6M; GPS Phase 3 nears 80th-event final analysis","bullets":["Q2 2026 net loss $9.6M ($0.05/sh) vs $6.6M ($0.07/sh) in Q2 2025; H1 loss $18.0M.","R&D expense $6.3M in Q2 2026 (vs $3.9M) on BLA prep for GPS; G&A $4.4M (vs $3.0M).","Cash and equivalents $138.3M as of June 30, 2026.","Phase 3 REGAL (GPS) in AML will conduct final analysis after pre-specified 80th event; timing unannounced.","28 patients enrolled in Phase 2 SLS009 frontline AML; topline data expected Q4 2026; preclinical PDAC data upcoming."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-26-000013","json":"https://secwatch.observer/filing/0001390478-26-000013.json","markdown":"https://secwatch.observer/filing/0001390478-26-000013.md","text":"https://secwatch.observer/filing/0001390478-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/0001390478-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:09:23.406001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}